Last update 04 Nov 2024

Glumetinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-(1-methyl-1h-pyrazol-4-yl)-1-((6-(1-methyl-1h-pyrazol-4-yl)imidazo(1,2-a)pyridin-3-yl)sulfonyl)-1h-pyrazolo(4,3-b)pyridine, Gumarontinib, Gumarontinib Hydrate
+ [5]
Target
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Conditional marketing approval (CN), Priority Review (CN), Special Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC21H17N9O2S
InChIKeyRYBLECYFLJXEJX-UHFFFAOYSA-N
CAS Registry1642581-63-2

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
c-Met positive non-small cell lung cancer
JP
24 Jun 2024
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
CN
07 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2
US
05 Nov 2020
Non-Small Cell Lung CancerPhase 2
US
05 Nov 2020
Non-Small Cell Lung CancerPhase 2
JP
05 Nov 2020
Non-Small Cell Lung CancerPhase 2
JP
05 Nov 2020
metastatic non-small cell lung cancerPhase 2
CN
11 May 2020
metastatic non-small cell lung cancerPhase 2
CN
11 May 2020
Recurrent Non-Small Cell Lung CancerPhase 2
CN
18 Nov 2019
c-Met positive Adenocarcinoma of EsophagusPhase 2
CN
31 Jul 2019
c-Met positive Adenocarcinoma of EsophagusPhase 2
CN
31 Jul 2019
Advanced Lung Non-Small Cell CarcinomaPhase 2
US
15 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
32
(pghyyjpcgw) = tnekdyatta fngbcunieu (hhmqerdwee, 63.6 - 92.8)
Positive
01 Jan 2024
Phase 1/2
84
Gumarontinib 300 mg
ckcenwdrhq(melthvztub) = 32/84, 38% ihosmudygo (yathhfpimz )
-
01 May 2023
Phase 1
32
qfuqwfsvdb(qcneisdqfc) = jjelnvfxxj zkftbyysgz (qjjqkbbuzj, 21.1 - 56.3)
Positive
03 Dec 2022
(treatment naïve patients)
qfuqwfsvdb(qcneisdqfc) = ihzofqxxjl zkftbyysgz (qjjqkbbuzj, 15.2 - 72.3)
Phase 2
30
cdpzjvicup(tunbqzsssr) = iwflwahxwu bcinicvucl (rdgharzjlt, [40.6 - 77.3])
-
03 Dec 2022
Phase 1
19
yeyvlzdzsg(dcmhstzvqz) = nbusfcobka nppfyatdbz (orkqbufbdg )
-
01 Mar 2021
Phase 1
18
gomsntzhit(owixuogiia) = Peripheral edema (n = 1, 5.5%), hypothyroidism (n = 1, 5.5%) oipztuapbf (eofjrnxxie )
Positive
25 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free